Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded up 9.9% during mid-day trading on Tuesday . The company traded as high as $16.43 and last traded at $16.39. 761,367 shares traded hands during mid-day trading, a decline of 9% from the average session volume of 834,523 shares. The stock had previously closed at $14.91.

A number of equities research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 18th. Finally, BidaskClub downgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $33.63.

The company has a market cap of $868.08 million, a PE ratio of 32.46 and a beta of 0.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.08). The company had revenue of $47.71 million during the quarter, compared to analysts’ expectations of $51.74 million. Vanda Pharmaceuticals had a net margin of 10.92% and a return on equity of 8.07%. Vanda Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the firm posted $0.14 earnings per share. On average, research analysts expect that Vanda Pharmaceuticals Inc. will post 0.06 EPS for the current fiscal year.

In related news, CFO James Patrick Kelly sold 8,751 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $19.88, for a total transaction of $173,969.88. Following the sale, the chief financial officer now directly owns 218,497 shares of the company’s stock, valued at approximately $4,343,720.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mihael Hristos Polymeropoulos sold 6,500 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $20.22, for a total transaction of $131,430.00. Following the sale, the chief executive officer now directly owns 1,217,136 shares in the company, valued at $24,610,489.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 209,371 shares of company stock worth $3,483,605. 8.20% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Comerica Bank increased its stake in Vanda Pharmaceuticals by 1.4% during the 1st quarter. Comerica Bank now owns 51,842 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 725 shares during the period. Piedmont Investment Advisors Inc. increased its stake in Vanda Pharmaceuticals by 5.9% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 13,198 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 737 shares during the period. Advisor Group Inc. increased its stake in Vanda Pharmaceuticals by 27.3% during the 1st quarter. Advisor Group Inc. now owns 3,712 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 796 shares during the period. Thrivent Financial for Lutherans increased its stake in Vanda Pharmaceuticals by 2.2% during the 4th quarter. Thrivent Financial for Lutherans now owns 37,074 shares of the biopharmaceutical company’s stock worth $969,000 after buying an additional 815 shares during the period. Finally, Rhumbline Advisers increased its stake in Vanda Pharmaceuticals by 0.6% during the 1st quarter. Rhumbline Advisers now owns 149,949 shares of the biopharmaceutical company’s stock worth $2,759,000 after buying an additional 832 shares during the period. 99.84% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Vanda Pharmaceuticals (VNDA) Shares Up 9.9%” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/vanda-pharmaceuticals-vnda-shares-up-9-9/3020275.html.

Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: Options Trading

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.